Yeshitila Gebremichael
About Yeshitila Gebremichael
Yeshitila Gebremichael is the Associate Director of Quantitative Systems Pharmacology at Bristol Myers Squibb, with extensive experience in pharmacology, toxicology, and biomedical engineering.
Current Title and Role
Yeshitila Gebremichael is currently serving as the Associate Director of Quantitative Systems Pharmacology at Bristol Myers Squibb in Princeton, New Jersey. His role involves leading initiatives and developing models to predict the pharmacokinetic and pharmacodynamic behaviors of drug candidates.
Previous Experience at Valo
From 2021 to 2023, Yeshitila Gebremichael worked as a Senior Staff Data Scientist specializing in Quantitative Pharmacology at Valo in Raleigh, North Carolina. During his two-year tenure, he contributed to the development and application of quantitative systems models to support drug discovery and development.
Role and Contributions at DILIsym Services
Yeshitila Gebremichael was a Scientist II focusing on Quantitative Systems Toxicology at DILIsym Services, Inc., a SimulationsPlus Company, from 2017 to 2021. Based in Research Triangle Park, North Carolina, he worked on projects involving the simulation of drug-induced liver injury (DILI) and contributed to the advancement of predictive toxicology.
Academic and Research Experience
Yeshitila Gebremichael has an extensive academic background, including a period as a Research Scientist at the University of Georgia College of Engineering, where he worked on quantitative systems pharmacology modeling. He also served as a Teaching Fellow at Harvard Extension School for a Machine Learning & Data Mining course and was an Assistant Professor in Biomedical Engineering at Wayne State University for seven years.
Education and Postdoctoral Fellowship
Yeshitila Gebremichael completed his Doctor of Philosophy (Ph.D.) in Chemical Physics at the University of Maryland, College Park, MD. He then pursued a postdoctoral fellowship at the Center for Biophysical Modeling and Simulation, Department of Chemistry, University of Utah, from 2004 to 2006, laying the foundation for his multidisciplinary expertise in soft condensed matter physics, biomedical engineering, neuroscience, physiology, pharmacology, and toxicology.